Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 1,119 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Nonsmall Cell Lung Cancer, Stage IV Clear all
Completed Phase 2 Interventional

Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

NCT00097214
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Carboplatin, Cetuximab
Drug · Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Bentonville, Arkansas • Tucker, Georgia • Evanston, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2010 · Synced Oct 23, 2026, 4:03 AM EDT
Completed Phase 1 Interventional

Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer

NCT01998126
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Ipilimumab, Erlotinib, Crizotinib, Nivolumab
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Oct 23, 2026, 4:03 AM EDT
Completed Phase 3 Interventional Results available

A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

NCT02713867
View directory record Official record
Conditions
Lung Cancer
Interventions
Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
77
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 70 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 23, 2026, 4:03 AM EDT
Terminated Phase 3 Interventional Results available

Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer

NCT00096265
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
3-Dimensional Conformal Radiation Therapy, Erlotinib Hydrochloride, Stereotactic Radiosurgery, Temozolomide
Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
80
States / cities
Scottsdale, Arizona • Burbank, California • Los Angeles, California + 67 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 23, 2026, 4:03 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-small Cell Lung Cancer

NCT00003072
View directory record Official record
Conditions
Lung Cancer, Neurotoxicity, Ovarian Cancer
Interventions
amifostine trihydrate, carboplatin, paclitaxel
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1998
U.S. locations
4
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2012 · Synced Oct 23, 2026, 4:03 AM EDT
Terminated Phase 2 Interventional Results available

Photodynamic Therapy Using HPPH in Treating Patients With Advanced Non-Small Cell Lung Cancer That Blocks the Air Passages

NCT00528775
View directory record Official record
Conditions
Lung Cancer
Interventions
HPPH, endoscopic procedure
Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Oct 23, 2026, 4:03 AM EDT
Completed Phase 2 Interventional Results available

Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer

NCT00687297
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Cancer
Interventions
vandetanib induction, Docetaxel, Carboplatin, Placebo, Vandetanib maintenance
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
30
States / cities
Boca Raton, Florida • Lakeland, Florida • Rockford, Illinois + 26 more
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 23, 2026, 4:03 AM EDT
Recruiting Phase 2 Interventional

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

NCT06495125
View directory record Official record
Conditions
Advanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Avutometinib, Biopsy, Biospecimen Collection, Computed Tomography, Defactinib, Nivolumab, Positron Emission Tomography
Drug · Procedure · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 23, 2026, 4:03 AM EDT
Active, not recruiting Phase 3 Interventional

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

NCT06635824
View directory record Official record
Conditions
PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
Interventions
Acasunlimab, Pembrolizumab, Docetaxel
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
36
States / cities
Tucson, Arizona • Los Angeles, California • Vallejo, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 4:03 AM EDT
Completed Phase 3 Interventional Results available

A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

NCT02864251
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Nivolumab, Ipilimumab, Pemetrexed, Cisplatin, Carboplatin
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
18
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 23, 2026, 4:03 AM EDT
Completed Phase 2 Interventional

A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer

NCT01496742
View directory record Official record
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
Placebo, RO5490258, bevacizumab [Avastin], cisplatin/carboplatin, paclitaxel, pemetrexed
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
32
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Bakersfield, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 23, 2026, 4:03 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00601094
View directory record Official record
Conditions
Lung Cancer
Interventions
autologous dendritic cell-adenovirus CCL21 vaccine
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
21 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 23, 2026, 4:03 AM EDT
Recruiting Phase 3 Interventional

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT07222566
View directory record Official record
Conditions
Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC), Metastatic Non Small Cell Lung Cancer, Lung Cancer
Interventions
PF-08634404, Pembrolizumab, Chemotherapy Regimen 1, Chemotherapy Regimen 2
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
226
States / cities
Bullhead City, Arizona • Chandler, Arizona • Gilbert, Arizona + 164 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 23, 2026, 4:03 AM EDT
Recruiting Phase 2 Interventional

Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT05168566
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Sutetinib Maleate Capsule
Drug
Lead sponsor
Teligene US
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
8
States / cities
Glendale, California • Washington D.C., District of Columbia • Athens, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 23, 2026, 4:03 AM EDT
Terminated Phase 2 Interventional Results available

A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC

NCT05144529
View directory record Official record
Conditions
Lung Cancer Metastatic
Interventions
Nivolumab, Ipilimumab, Evolocumab
Drug
Lead sponsor
Eziafa Oduah, MD, PhD, MPH
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 23, 2026, 4:03 AM EDT
Recruiting Not applicable Interventional

Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer

NCT03199651
View directory record Official record
Conditions
Cigarette Smoker, Current Smoker, Lung Adenocarcinoma, Squamous Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions
Best Practice, Biospecimen Collection, Laboratory Biomarker Analysis, Medical Chart Review, Quality-of-Life Assessment, Questionnaire Administration, Smoking Cessation Intervention
Other · Procedure · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3,584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 23, 2026, 4:03 AM EDT
Completed Phase 1 Interventional

Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer

NCT00128622
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
denileukin diftitox, recombinant fowlpox-CEA(6D)/TRICOM vaccine, therapeutic autologous dendritic cells
Biological
Lead sponsor
H. Kim Lyerly
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 12, 2012 · Synced Oct 23, 2026, 4:03 AM EDT
Completed Phase 2Phase 3 Interventional

Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer

NCT00006229
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, rebimastat
Drug
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
18 Years to 120 Years
Enrollment
774 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
18
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Oct 23, 2026, 4:03 AM EDT
Completed Phase 2 Interventional Results available

Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

NCT04484142
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
DS-1062a
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
28
States / cities
Phoenix, Arizona • La Jolla, California • Santa Monica, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 23, 2026, 4:03 AM EDT
Completed Phase 3 Interventional Results available

Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

NCT00377156
View directory record Official record
Conditions
Breast Cancer, Cognitive/Functional Effects, Lung Cancer, Metastatic Cancer, Prostate Cancer
Interventions
radiation therapy, stereotactic radiosurgery
Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
60
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Modesto, California + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2022 · Synced Oct 23, 2026, 4:03 AM EDT
Completed No phase listed Observational

Immune Response Under Immunotherapy in Metastatic NSCLC: Sputum, Blood Samples and Microbioata Study

NCT04804137
View directory record Official record
Conditions
Non-squamous Lung Cancer, Metastatic Lung Cancer
Interventions
Blood, sputum, saliva, stool
Other
Lead sponsor
University Hospital, Tours
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 23, 2026, 4:03 AM EDT
Completed Phase 1 Interventional

Immunotoxin Therapy in Treating Patients With Advanced Cancer

NCT00006981
View directory record Official record
Conditions
Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Malignant Mesothelioma, Ovarian Cancer, Pancreatic Cancer, Primary Peritoneal Cavity Cancer
Interventions
SS1(dsFv)-PE38 immunotoxin
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 23, 2026, 4:03 AM EDT
Completed Phase 2 Interventional

Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer

NCT00030407
View directory record Official record
Conditions
Lung Cancer
Interventions
Celecoxib, Docetaxel
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2013 · Synced Oct 23, 2026, 4:03 AM EDT
Completed Phase 1Phase 2 Interventional

MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC

NCT01310244
View directory record Official record
Conditions
Stage IV Non-small Cell Lung Cancer
Interventions
Belinostat, Carboplatin, Paclitaxel
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
4
States / cities
Huntsville, Alabama • Santa Monica, California • Boynton Beach, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Oct 23, 2026, 4:03 AM EDT